ArticleFrontiers in medicine2026
Case Report: Albumin combined with plasma exchange in the treatment of refractory thrombotic thrombocytopenic purpura.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to analyze the clinical characteristics and causes of misdiagnosis in patients with thrombotic thrombocytopenic purpura (TTP) presenting with initial neurological symptoms, so as to provide reference for reducing misdiagnosis; to explore the feasibility and efficacy of albumin combined with plasma exchange in the treatment of TTP patients when plasma inventory is insufficient; and to put forward key precautions for TTP diagnosis and treatment, so as to provide strategic support for the treatment of similar cases. Methods: Clinical data of the patient (medical history, examination results, diagnosis and treatment records, etc.) were collected retrospectively; albumin combined with plasma exchange was adopted when plasma inventory was insufficient; laboratory indicators and symptom recovery were dynamically monitored to evaluate the effectiveness and safety of the treatment; misdiagnosis risks and the current status of alternative treatment were analyzed combined with literature review. Conclusion: Thrombotic thrombocytopenic purpura with initial neurological symptoms is easily confused with cerebral infarction, and thrombocytopenia of unknown origin is a key clue for differential screening. TTP should be excluded before platelet transfusion; when plasma inventory is insufficient, albumin combined with plasma exchange is feasible and effective for the treatment of AB-blood-type TTP, which can provide an alternative strategy for clinical practice; early diagnosis, timely targeted treatment and multidisciplinary collaboration are the keys to improving the prognosis of TTP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.